Harmony Biosciences Holdings (HRMY) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Harmony Biosciences Holdings stock (HRMY) is currently trading at $27.59. Harmony Biosciences Holdings PE ratio is 10.23. Harmony Biosciences Holdings PS ratio (Price-to-Sales) is 1.85. Analyst consensus price target for HRMY is $42.00. WallStSmart rates HRMY as Hold.
- HRMY PE ratio analysis and historical PE chart
- HRMY PS ratio (Price-to-Sales) history and trend
- HRMY intrinsic value — DCF, Graham Number, EPV models
- HRMY stock price prediction 2025 2026 2027 2028 2029 2030
- HRMY fair value vs current price
- HRMY insider transactions and insider buying
- Is HRMY undervalued or overvalued?
- Harmony Biosciences Holdings financial analysis — revenue, earnings, cash flow
- HRMY Piotroski F-Score and Altman Z-Score
- HRMY analyst price target and Smart Rating
Harmony Biosciences Holdings
📊 No data available
Try selecting a different time range
HRMY Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Harmony Biosciences Holdings (HRMY)
HRMY trades 99% above its Graham fair value of $18.43, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Harmony Biosciences Holdings (HRMY) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, price/sales, price/book. Concerns around eps growth. Fundamentals are solid but monitor weak areas for improvement.
Harmony Biosciences Holdings (HRMY) Key Strengths (6)
91.14% of shares held by major funds and institutions
Every $100 of equity generates $21 in profit
Paying $1.85 for every $1 of annual revenue
Trading at 1.84x book value, attractively priced
Strong revenue growth at 21.10% annually
Strong profitability: $18 kept per $100 revenue
Supporting Valuation Data
Harmony Biosciences Holdings (HRMY) Areas to Watch (3)
Earnings declining -55.00%, profits shrinking
Small-cap company with higher risk but more growth potential
Decent operational efficiency, solid but not exceptional
Harmony Biosciences Holdings (HRMY) Detailed Analysis Report
Overall Assessment
This company scores 62/100 in our Smart Analysis, earning a C+ grade. Out of 9 metrics analyzed, 6 register as strengths (avg 8.5/10) while 3 fall into concern territory (avg 3.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Return on Equity, Price/Sales. Valuation metrics including Price/Sales (1.85), Price/Book (1.84) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 20.70%, Profit Margin at 18.30%. Growth metrics are encouraging with Revenue Growth at 21.10%.
The Bear Case
The primary concerns are EPS Growth, Market Cap, Operating Margin. Growth concerns include EPS Growth at -55.00%, which may limit upside. Profitability pressure is visible in Operating Margin at 15.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 20.70% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 21.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Return on Equity) and negatives (EPS Growth, Market Cap). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HRMY Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HRMY's Price-to-Sales ratio of 1.85x sits near its historical average of 1.88x (17th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 3% below its historical high of 1.9x set in Mar 2026, and 0% above its historical low of 1.84x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Harmony Biosciences Holdings (HRMY) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Harmony Biosciences Holdings is a strong growth company balancing expansion with improving profitability. Revenue reached 868M with 21% growth year-over-year. Profit margins of 18.3% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 20.7% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 126M in free cash flow and 126M in operating cash flow. Earnings are translating into actual cash generation.
Earnings fell 55% YoY while revenue grew 21%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Growth sustainability: can Harmony Biosciences Holdings maintain 21%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Harmony Biosciences Holdings.
Bottom Line
Harmony Biosciences Holdings offers an attractive blend of growth (21% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Harmony Biosciences Holdings(HRMY)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.